Inovio Pharmaceuticals Balance Sheet Health
Financial Health criteria checks 5/6
Inovio Pharmaceuticals has a total shareholder equity of $117.3M and total debt of $16.8M, which brings its debt-to-equity ratio to 14.3%. Its total assets and total liabilities are $171.0M and $53.6M respectively.
Key information
14.3%
Debt to equity ratio
US$16.77m
Debt
Interest coverage ratio | n/a |
Cash | US$145.29m |
Equity | US$117.35m |
Total liabilities | US$53.60m |
Total assets | US$170.95m |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: GBM's short term assets ($153.1M) exceed its short term liabilities ($42.6M).
Long Term Liabilities: GBM's short term assets ($153.1M) exceed its long term liabilities ($11.0M).
Debt to Equity History and Analysis
Debt Level: GBM has more cash than its total debt.
Reducing Debt: GBM's debt to equity ratio has increased from 0% to 14.3% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: GBM has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: GBM has sufficient cash runway for 1.8 years if free cash flow continues to reduce at historical rates of 16.8% each year.